• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Re: Active Surveillance Plus Enzalutamide Monotherapy vs Active Surveillance Alone in Patients with Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial.

作者信息

Kesch Claudia, Hadaschik Boris A

机构信息

Department of Urology, West German Cancer Center, University of Duisburg, Essen and German Cancer Consortium, University Hospital Essen, Essen, Germany.

Department of Urology, West German Cancer Center, University of Duisburg, Essen and German Cancer Consortium, University Hospital Essen, Essen, Germany.

出版信息

Eur Urol. 2022 Nov;82(5):572. doi: 10.1016/j.eururo.2022.07.030. Epub 2022 Aug 9.

DOI:10.1016/j.eururo.2022.07.030
PMID:35961870
Abstract
摘要

相似文献

1
Re: Active Surveillance Plus Enzalutamide Monotherapy vs Active Surveillance Alone in Patients with Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial.回复：低风险或中风险局限性前列腺癌患者中主动监测联合恩杂鲁胺单药治疗与单纯主动监测的比较：ENACT随机临床试验
Eur Urol. 2022 Nov;82(5):572. doi: 10.1016/j.eururo.2022.07.030. Epub 2022 Aug 9.
2
Enzalutamide Monotherapy vs Active Surveillance in Patients With Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial.恩杂鲁胺单药治疗与主动监测在低危或中危局限性前列腺癌患者中的比较：ENACT 随机临床试验。
JAMA Oncol. 2022 Aug 1;8(8):1128-1136. doi: 10.1001/jamaoncol.2022.1641.
3
Active surveillance versus enzalutamide for low-risk prostate cancer - was it really a trial we needed?主动监测与恩杂鲁胺治疗低风险前列腺癌——这真的是我们需要的试验吗？
BJU Int. 2022 Nov;130(5):580-581. doi: 10.1111/bju.15860. Epub 2022 Aug 2.
4
Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study.CARD 研究：卡巴他赛对比阿比特龙或恩杂鲁胺用于转移性去势抵抗性前列腺癌老年患者的疗效和安全性。
Eur Urol. 2021 Oct;80(4):497-506. doi: 10.1016/j.eururo.2021.06.021. Epub 2021 Jul 15.
5
Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial.来自PREVAIL试验的恩杂鲁胺用于未经化疗的转移性去势抵抗性前列腺癌男性患者的五年生存预测及安全性结果
Eur Urol. 2020 Sep;78(3):347-357. doi: 10.1016/j.eururo.2020.04.061. Epub 2020 Jun 9.
6
Enzalutamide Monotherapy in the EMBARK Trial Should Be Practice-changing and Existing Data Suggest How to Mitigate Toxicity.在 EMBARK 试验中，恩杂鲁胺单药治疗应该改变实践，并且现有数据提示如何减轻毒性。
Eur Urol Oncol. 2024 Oct;7(5):971-972. doi: 10.1016/j.euo.2024.06.001. Epub 2024 Jun 29.
7
Continuing enzalutamide with docetaxel in castration-resistant prostate cancer.在去势抵抗性前列腺癌中持续使用恩杂鲁胺联合多西他赛。
Lancet Oncol. 2022 Nov;23(11):1345-1347. doi: 10.1016/S1470-2045(22)00614-3. Epub 2022 Oct 18.
8
A European, prospective, observational study of enzalutamide in patients with metastatic castration-resistant prostate cancer: PREMISE.一项关于转移性去势抵抗性前列腺癌患者恩扎卢胺的欧洲、前瞻性、观察性研究：PREMISE。
Int J Cancer. 2022 Mar 1;150(5):837-846. doi: 10.1002/ijc.33845. Epub 2021 Nov 8.
9
A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone.一项评估帕博利珠单抗联合恩扎卢胺治疗转移性去势抵抗性前列腺癌的 II 期单臂研究，入组的患者为既往接受恩扎卢胺单药治疗后进展的男性。
J Immunother Cancer. 2020 Jul;8(2). doi: 10.1136/jitc-2020-000642.
10
Enzalutamide With Radiation Therapy for Intermediate-Risk Prostate Cancer: A Phase 2 Study.恩杂鲁胺联合放射治疗中危前列腺癌：一项 2 期研究。
Int J Radiat Oncol Biol Phys. 2021 Aug 1;110(5):1416-1422. doi: 10.1016/j.ijrobp.2021.02.027. Epub 2021 Feb 23.

引用本文的文献

1
Pathological Effects of Apalutamide in Lower-risk Prostate Cancer: Results From a Phase II Clinical Trial.阿帕鲁胺治疗低危前列腺癌的病理效应：来自 II 期临床试验的结果。
J Urol. 2023 Feb;209(2):354-363. doi: 10.1097/JU.0000000000003038. Epub 2023 Feb 1.